1. Academic Validation
  2. Akt Activation Mediates Acquired Resistance to Fibroblast Growth Factor Receptor Inhibitor BGJ398

Akt Activation Mediates Acquired Resistance to Fibroblast Growth Factor Receptor Inhibitor BGJ398

  • Mol Cancer Ther. 2017 Apr;16(4):614-624. doi: 10.1158/1535-7163.MCT-15-1010.
Jharna Datta 1 Senthilkumar Damodaran 1 2 Hannah Parks 1 Cristina Ocrainiciuc 1 Jharna Miya 1 Lianbo Yu 3 Elijah P Gardner 1 Eric Samorodnitsky 1 Michele R Wing 1 Darshna Bhatt 1 John Hays 1 2 Julie W Reeser 1 Sameek Roychowdhury 4 2 5
Affiliations

Affiliations

  • 1 Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio.
  • 2 Division of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, Ohio.
  • 3 Center for Biostatistics, Department of Biomedical Informatics, The Ohio State University, Columbus, Ohio.
  • 4 Comprehensive Cancer Center, The Ohio State University, Columbus, Ohio. sameek.roychowdhury@osumc.edu.
  • 5 Department of Pharmacology, The Ohio State University, Columbus, Ohio.
Abstract

Activation of FGFR signaling through mutations, amplifications, or fusions involving FGFR1, 2, 3, or 4 is seen in multiple tumors, including lung, bladder, and cholangiocarcinoma. Currently, several clinical trials are evaluating the role of novel FGFR inhibitors in solid tumors. As we move forward with FGFR inhibitors clinically, we anticipate the emergence of resistance with treatment. Consequently, we sought to study the mechanism(s) of acquired resistance to FGFR inhibitors using annotated Cancer cell lines. We identified Cancer cell lines that have activating mutations in FGFR1, 2, or 3 and treated them chronically with the selective FGFR Inhibitor, BGJ398. We observed resistance to chronic BGJ398 exposure in DMS114 (small-cell lung Cancer, FGFR1 amplification) and RT112 (urothelial carcinoma, FGFR3 fusion/amplification) cell lines based on viability assays. Reverse-phase protein array (RPPA) analysis showed increased phosphorylation of Akt (T308 and S473) and its downstream target GSK3 (S9 and S21) in both the resistant cell lines when compared with matching controls. Results of RPPA were confirmed using immunoblots. Consequently, the addition of an Akt Inhibitor (GSK2141795) or siRNA was able to restore sensitivity to BGJ398 in resistant cell lines. These data suggest a role for Akt pathway in mediating acquired resistance to FGFR inhibition. Mol Cancer Ther; 16(4); 614-24. ©2017 AACR.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-15965
    99.74%, Akt抑制剂
    Akt